Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 3;23(7):78.
doi: 10.1007/s11912-021-01068-0.

Cardiovascular Toxicities of CAR T-cell Therapy

Nikita P Patel  1 , Peter G Doukas  1 , Leo I Gordon  2 , Nausheen Akhter  3
Affiliations
Review

Cardiovascular Toxicities of CAR T-cell Therapy

Nikita P Patel et al. Curr Oncol Rep. .

Abstract

Purpose of review: This review provides a contemporary overview of current studies outlining the incidence and characteristics of CAR T-cell cardiotoxicity in an effort to identify future directions for research and potential opportunities for prevention and intervention.

Recent findings: Cardiovascular events occurred in anywhere between 10 and 36% of patients in CAR T-cell clinical trials, ranging from tachycardia, hypotension, arrhythmia, decreased left ventricular systolic function to cardiogenic shock and death. Cardiac events are more often associated higher grades (> 2) of cytokine release syndrome and frequently proceeded by an elevated troponin. There is a growing recognition of cardiotoxicities of CAR T-cell therapy but has a limited study in this area. The mechanism of left ventricular dysfunction due to CAR T-cell therapy is also unknown. As CAR T-cell use expands, it becomes imperative to truly understand the mechanism behind cardiac injury and to assess long-term follow-up data as this will allow for surveillance, early intervention, and potentially prevention of cardiotoxicity.

Keywords: CAR T-cell; Cardio-oncology; Cardiotoxicity; Chimeric antigen receptor; Cytokine release syndrome.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance
    1. Perica K, Varela JC, Oelke M, Schneck J. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J. 2015;6(1):e0004. - DOI
    1. Tisagenlecleucel STN 125646 Approval Letter. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Aug 2017. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-produ... . Accessed 30 Jan 2021.
    1. Axicabtagene Ciloleucel STN BL 125643 Approval Letter. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Oct 2017. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-produ... . Accessed 30 Jan 2021.
    1. Brexucabtagene Autoleucel STN BL 125703 Approval Letter. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Jul 2020. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-produ... . Accessed 30 Jan 2021.
    1. Lisocabtagene Maraleucel STN BLA 125714 Approval Letter. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Feb 2021. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-produ... . Accessed 6 Feb 2021.

MeSH terms

Substances

LinkOut - more resources